Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 11 009 M
EBIT 2016 3 190 M
Net income 2016 1 054 M
Debt 2016 11 910 M
Yield 2016 -
Sales 2017 12 709 M
EBIT 2017 3 799 M
Net income 2017 2 119 M
Debt 2017 11 383 M
Yield 2017 -
P/E ratio 2016 30,85
P/E ratio 2017 15,18
EV / Sales2016 3,13x
EV / Sales2017 2,67x
Capitalization 22 560 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted... 
Sector
Pharmaceuticals
Calendar
03/01Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
02/24MYLAN NV : annual earnings release
02/17 MYLAN NV : Blog Coverage The Biologics License Application for Mylan-Biocon's Pr..
02/16 MYLAN : U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Bioco..
02/14 MYLAN : Applauds the Generic Pharmaceutical Association's Rebrand to the Associa..
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
02/06 MYLAN : agreed to pay $96.5 million in Provigil antitrust class action
02/03 MYLAN : to Host Investor Day on March 1, 2017 in New York City
02/01DJMore Headaches for Drugmakers -- WSJ
01/30 MYLAN : Wins U.S. District Court Ruling Related to Copaxone® 40 mg/mL Patents
01/30 As Teva wins U.S. approval for GSK Advair copy, main fight yet to come
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/23 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 49,6 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%22 560
JOHNSON & JOHNSON5.63%333 891
ROCHE HOLDING LTD.5.98%210 192
PFIZER INC.4.86%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.11.86%182 412
More Results